X_8 is any amino acid residue;

X_9 is an aliphatic residue;

X_{10} is any amino acid residue;

Z_3 is an optional 1 to 5 residue peptide or peptide analog;

Z_4 is –C(O)OR or –C(O)NRR;

each R is independently hydrogen, (C_1-C_6) alkyl, (C_2-C_6) alkenyl, (C_2-C_6) alkynyl or (C_6-C_{14}) aryl;

B1 each "–" between residues X_1 through X_{10}, Z_2 and X_1 and X_{10} and Z_3 independently represents an amide linkage, a substituted amide linkage or an isostere of an amide linkage; and

each "~" represents a bond.

Please replace claim 12 with the following:

12. (once amended) The compound of claim 1 which is a 10-20 residue peptide or peptide analog according to formula (I):

B2 (I) Z_1~Z_2-X_1-X_2-X_3-X_4-X_5-X_6-X_7-X_8-X_9-X_{10}-Z_3~Z_4

or a pharmaceutically-acceptable salt thereof, wherein:

Z_1 is R-C(O)-NR- or RRN-;

Z_2 is an optional 1 to 5 residue peptide or peptide analog;

X_1 is any amino acid residue;

X_2 is any amino acid residue;

X_3 is a hydrophobic residue or a hydroxyl-substituted aliphatic residue;

X_4 is any amino acid residue;

X_5 is a hydrophobic residue or Gly;

X_6 is a hydrophobic or a hydrophilic residue;

X_7 is Gly, an amide-substituted polar residue or a hydrophobic residue;

X_8 is any amino acid residue;

X_9 is an aliphatic residue;

X_{10} is any amino acid residue;

Z_3 is an optional 1 to 5 residue peptide or peptide analog;

Z_4 is –C(O)OR or –C(O)NRR;

each R is independently hydrogen, C_1C_6) alkyl, C_2-C_6) alkenyl, C_2-C_6) alkynyl or C_6-C_{14}) aryl;

each "–" between residues X_1 through X_{10}, Z_2 and X_1 and X_{10} and Z_3 independently represents an amide linkage, a substituted amide linkage or an isostere of an amide linkage; and

each "~" represents a bond.